- Home
- MGIC vs TGTX Comparison
MGIC vs TGTX Comparison
Compare MGIC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- TGTX
- Stock Information
- Founded
- MGIC 1983
- TGTX 1993
- Country
- MGIC Israel
- TGTX United States
- Employees
- MGIC N/A
- TGTX N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MGIC Technology
- TGTX Health Care
- Exchange
- MGIC Nasdaq
- TGTX Nasdaq
- Market Cap
- MGIC N/A
- TGTX 5.4B
- IPO Year
- MGIC 1991
- TGTX 1995
- Fundamental
- Price
- MGIC $11.89
- TGTX $31.23
- Analyst Decision
- MGIC Buy
- TGTX Strong Buy
- Analyst Count
- MGIC 1
- TGTX 6
- Target Price
- MGIC $15.00
- TGTX $40.67
- AVG Volume (30 Days)
- MGIC 44.1K
- TGTX 2.0M
- Earning Date
- MGIC 11-18-2024
- TGTX 02-26-2025
- Dividend Yield
- MGIC 1.70%
- TGTX N/A
- EPS Growth
- MGIC N/A
- TGTX N/A
- EPS
- MGIC 0.70
- TGTX N/A
- Revenue
- MGIC $535,482,999.00
- TGTX $264,790,000.00
- Revenue This Year
- MGIC $4.29
- TGTX $44.11
- Revenue Next Year
- MGIC $3.39
- TGTX $63.92
- P/E Ratio
- MGIC $17.20
- TGTX N/A
- Revenue Growth
- MGIC N/A
- TGTX 39.53
- 52 Week Low
- MGIC $9.38
- TGTX $12.84
- 52 Week High
- MGIC $13.40
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- MGIC 51.98
- TGTX 46.32
- Support Level
- MGIC $11.51
- TGTX $29.90
- Resistance Level
- MGIC $12.24
- TGTX $33.55
- Average True Range (ATR)
- MGIC 0.28
- TGTX 1.75
- MACD
- MGIC -0.07
- TGTX -0.39
- Stochastic Oscillator
- MGIC 43.86
- TGTX 17.45
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.